Avoro Capital Advisors LLCAvoro Capital Advisors LLC

Institutional investor · Portfolio as of Q4 2019

SEC EDGAR SourceSEC Filings

Top Holdings31 positions

Checking export access…
Activity:
Stock
Shares
Value
Weight
Avg Buy
Est. P&L
Held
Conviction
IMMUIMMUDelisted

IMMUNOMEDICS INC

24.5M$518.4M15.2%
4 qtrssince 2019-Q1
Increased
72
MRTXMRTXDelisted

MIRATI THERAPEUTICS INC

3.9M$496.1M14.6%
4 qtrssince 2019-Q1
Increased
63
ASNDASND
ADR

ASCENDIS PHARMA A/S

1.9M$259.5M7.6%$117.47+15.75%
4 qtrssince 2019-Q1
Decreased
0

IOVANCE BIOTHERAPEUTICS INC

8.8M$244.3M7.2%$9.82+180.97%
4 qtrssince 2019-Q1
Decreased
0

AVI BIOPHARMA INC

1.8M$227.1M6.7%$116.47+10.57%
4 qtrssince 2019-Q1
Increased
64
CNSTCNSTDelisted

CONSTELLATION PHARMCETICLS I

3.7M$172M5.0%
1 qtr
New
95

BIOMARIN PHARMACEUTICAL INC

2M$169.1M5.0%$84.82-0.27%
4 qtrssince 2019-Q1
Decreased
0
ARGXARGX
ADR

ARGENX SE - ADR

936,500$150.3M4.4%$128.85+25.58%
4 qtrssince 2019-Q1
Increased
63

HORIZON THERAPEUTICS PLC

4M$144.8M4.3%
3 qtrssince 2019-Q2
Unchanged
0

uniQure N.V.

1.7M$121.8M3.6%$64.81+10.66%
2 qtrssince 2019-Q3
Increased
90

Karyopharm Therapeutics Inc.

5.9M$113.1M3.3%
MYOKMYOKDelisted

MYOKARDIA INC

1.5M$112.2M3.3%
4 qtrssince 2019-Q1
Decreased
0

AMICUS THERAPEUTICS INC

11.2M$109.1M3.2%$12.97-26.53%
4 qtrssince 2019-Q1
Increased
56
ZGNXZGNXDelisted

ZOGENIX INC

2M$104.3M3.1%
4 qtrssince 2019-Q1
Increased
60
ATNXATNXDelisted

ATHENEX INC

5.3M$80.3M2.4%
3 qtrssince 2019-Q2
Decreased
0
ADVMADVMDelisted

ADVERUM BIOTECHNOLOGIES INC

5.3M$60.5M1.8%
TCDAQTCDAQDelisted

TRICIDA INC

1.6M$58.9M1.7%
4 qtrssince 2019-Q1
Decreased
0
AMRNAMRN
ADR

Amarin Corporation plc

1.9M$40.7M1.2%

MADRIGAL PHARMACEUTICALS INC

349,000$31.8M0.9%$122.42-26.40%
4 qtrssince 2019-Q1
Decreased
0

XENON PHARMACEUTICALS INC

2.4M$31.5M0.9%$10.16+29.92%
4 qtrssince 2019-Q1
Unchanged
0
$3.4B
AUM
31
Positions
Q4 2019
Filing
Rating · 1.5
Quarterly Portfolio Change
+25%Q2'19$2.9B-17%Q3'19$2.4B+42%Q4'19$3.4B
Activity profile
$ moved · Q4'19
New16%Increased50%Decreased21%Exited13%
Composition
Equity vs derivatives
Equity100%Puts0%Calls0%
Holding period
Avg 3.1 quarters
<1Q19%1-4Q68%1-2Y0%2Y+13%

Avoro Capital Advisors LLC manages $3.4B across 31 positions as of Q4 2019. Top holdings: IMMU (15.2%), MRTX (14.6%), ASND (7.6%). Fund DNA: Balanced Allocator. HoldingsIntel Rating: 1.5/5.0.

Q4 2019 Summary

Active quarter - 5 new positions, 9 exits, 9 increased. Top move: CNST (NEW, conviction 95). Portfolio: $3.4B across 31 positions.

Top holdings by portfolio weight

Total AUM$3B
IMMU15.22%
MRTX14.57%
ASND7.62%
IOVA7.17%
SRPT6.67%
CNST5.05%
BMRN4.97%
ARGX4.41%
HZNP4.25%
QURE3.58%
Other3.32%

Portfolio allocation by GICS sector

Sectors2
Unknown53.67%
Healthcare46.33%

Behavioral investing profile

Checking access…
Balanced Allocator- primarily Unknown, Healthcare
Compare DNA across all funds
7-dimension quality assessment
Below Average(1.5 / 5.0)
Track RecordNo data
Conviction47
Concentration100
Checking access…

Position Outcomes

Best and worst performing positions by estimated return

Cost basis estimates based on full filing history using quarter-end prices. Actual transaction prices are not disclosed in 13F filings.

Similar Funds

Funds with similar investing DNA

Accumulation Streaks

Positions with 2+ consecutive quarters of increases - persistent directional conviction.

Security
4Q
OCULOCULOCULAR THERAPEUTIX INC
Q3 2025 Q2 2026+5.1M shares+$54.5M
3Q
UTHRUTHRUNITED THERAPEUTICS CORP
Q4 2025 Q2 2026+755,555 shares+$657.3M
2Q
ARWRARWRARROWHEAD PHARMACEUTICALS IN
Q1 2026 Q2 2026+730,555 shares+$220.2M
Checking access…

Data sourced from SEC EDGAR 13F filings. Not financial advice. Full disclaimer

Analytics tracking helps us improve the product. Essential functions stay on either way. How analytics data is used